Belamaf
(Belantamab)Phase 3Monoclonal antibody
GSKBelantamab is used to treat multiple myeloma, a type of blood cancer where abnormal plasma cells multiply in the bone marrow. It works by targeting and destroying cancer cells that have a specific protein on their surface.[1] Belamaf is currently being investigated across 10 indications[3], with its most advanced program in Phase 3.[1]
Belamaf is one of 143 biologic programs targeting Multiple Myeloma. It is currently in Phase 3.
10
Indications
60
Total Trials
38
Active Trials
142
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Empliciti
Bristol-Myers SquibbPhase 3
Fludara
SanofiPhase 3
Ninlaro
TakedaPhase 3
Venclexta
AbbViePhase 3
Belamaf
GSKPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Biaxin
AbbViePhase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Elranatamab
PfizerPhase 3
Vepesid
AAvyxa
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma39 trials
Show 36 more trials
ART3 trials
Monotherapy2 trials
Plasma Cell Myeloma2 trials
Recurrent Multiple Myeloma2 trials
12 more indications
Autoimmune Disease1 trial
Dexamethasone1 trial
Lenalidomide1 trial
Immune Thrombocytopenia1 trial
Relapsed/Refractory Multiple Myeloma1 trial
Myeloma Multiple1 trial
Myeloma1 trial
AL amyloidosis1 trial
Amyloidosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Belantamab. EMBL-EBI & Wellcome Sanger Institute.
- [4]